PLAT-E Cells

Plat-E (Platinum-E) is a retrovirus packaging cell line engineered from the human embryonic kidney 293T cell background. It was developed to provide a stable and efficient system for transient production of high-titer, ecotropic retroviruses. The cell line was constructed using novel packaging constructs in which the expression of viral structural genes – gag-pol and env – is driven by the human EF1α promoter, which is substantially more potent in 293T cells than the conventional MuLV long terminal repeat (LTR) promoter. This design ensures robust transcriptional activity and supports high-level production of viral components necessary for efficient retrovirus assembly and packaging.

Plat-E cells were generated through sequential stable transfection of pEnv-IRES-puror and pGag-pol-IRES-bsr constructs, which link the viral genes to antibiotic resistance markers via internal ribosome entry sites (IRES). This configuration guarantees that only cells expressing the essential viral genes also gain antibiotic resistance, allowing for selection of high-expressing subclones. The resulting Plat-E line consistently produces retroviruses with titers up to 1 × 107 infectious units per milliliter for at least four months when cultured under dual selection with puromycin and blasticidin. Northern blot, reverse transcriptase activity, and flow cytometry analyses confirmed that Plat-E exhibits significantly higher gag-pol and env expression than predecessor packaging lines such as Bosc23 and Phoenix-E.

Plat-E’s architecture minimizes the risk of generating replication-competent retrovirus (RCR) by limiting the packaging constructs to only the necessary coding regions of the viral structural genes and separating them onto different plasmids. This design requires at least three recombination events to produce RCR, thereby enhancing biosafety. Plat-E has proven useful in gene transfer applications, including efficient transduction of primary cells such as T cells and mast cells. Its performance and long-term stability make it a reliable platform for retroviral vector production in both basic research and preclinical gene therapy development.